Compare Samsara Inc (IOT) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Samsara Inc vs BIO-TECHNE Corp — how do they compare? Samsara Inc trades at $41.55 (market cap $24.14B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: Samsara Inc is far larger — about 2.1× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Samsara Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Samsara Inc for 19 Days and BIO-TECHNE Corp for 64 Days on average.
| IOT | TECH | |
|---|---|---|
Market Cap | $24.14B | $11.36B |
Volume | 5,372,580 | 5,390,331 |
Sector | Technology | Health |
52-Week High | $45.22 | $72.61 |
52-Week Low | $24.25 | $43.31 |
Typical Hold Time | 19 Days | 64 Days |
Enterprise Value | $23.38B | $11.39B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Samsara (IOT) trades at $41.22, up 1.75% today, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.20 vs. $0.16 expected, and revenue growth of 30% year-over-year. Analyst consensus is strongly bullish with a $51.15 price target, and recent news highlights partnerships and product launches like Samsara MCP for AI integration.
The outlook is positive given earnings momentum and large-customer expansion, but high valuation ratios (P/E 274.8, P/S 13.01) pose risks if growth slows. Key opportunities include sustained revenue growth and margin improvement, while risks involve competitive pressures and cash flow volatility from investing activities.
TECH trades at $72.45, near its 52-week high of $72.70 (Defense World, 2026-09-28), with a slight 0.11% decline over 24 hours. The stock shows a bullish technical signal, supported by moving averages, while fundamentals reveal a high P/E of 62.46 and net income margin of 14.97% for 2025. Recent news highlights shareholder approval of its acquisition by Merck KGaA at $73.00 per share (PRNewsWire, 2026-09-23), a key catalyst for near-term price action.
The outlook is mixed: the acquisition offers upside to the current price, but elevated valuation ratios pose risks if earnings growth falters. Analyst consensus is divided with 46% buy ratings, and net income volatility from 2022-2025 signals execution challenges. Investors should weigh the acquisition premium against fundamental sustainability in a competitive life sciences tools sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Samsara Inc
Samsara provides a connected operations cloud that uses IoT data to help businesses improve efficiency and safety. Its platform offers real-time visibility for fleet management, equipment monitoring, and industrial sites.
Read more on IOT →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
